These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37093589)

  • 1. The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mestre TA; McDermott MP; Lobo R; Ferreira JJ; Lang AE
    Mov Disord; 2023 Jul; 38(7):1346-1350. PubMed ID: 37093589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.
    Mestre TA; Shah P; Marras C; Tomlinson G; Lang AE
    Neurology; 2014 Apr; 82(16):1402-9. PubMed ID: 24658930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What influences placebo and nocebo responses in Parkinson's disease?
    Witek N; Stebbins GT; Goetz CG
    Mov Disord; 2018 Aug; 33(8):1204-1212. PubMed ID: 30132980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nocebo and lessebo effects.
    A Mestre T
    Int Rev Neurobiol; 2020; 153():121-146. PubMed ID: 32563285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mestre TA; Lang AE; Okun MS
    Mov Disord; 2016 Mar; 31(3):290-6. PubMed ID: 26952118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lessebo effect in randomized controlled trials of rituximab in patients with rheumatoid arthritis: a meta-analysis.
    Sung YK; Lee YH
    Z Rheumatol; 2023 Jan; 82(Suppl 1):44-50. PubMed ID: 34761312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.
    Choi JH; Lee JY; Cho JW; Koh SB; Yang YS; Yoo D; Shin CM; Kim HT
    Mov Disord; 2020 Nov; 35(11):1966-1976. PubMed ID: 32761955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
    Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
    Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    Mov Disord; 2021 Feb; 36(2):415-423. PubMed ID: 33073879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    van den Heuvel L; Evers LJW; Meinders MJ; Post B; Stiggelbout AM; Heskes TM; Bloem BR; Krijthe JH
    Mov Disord; 2021 Feb; 36(2):407-414. PubMed ID: 33107639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists for Parkinson's disease.
    Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis.
    Lopez L; Griffier R; Barnetche T; Lhomme E; Kostine M; Truchetet ME; Schaeverbeke T; Richez C
    Rheumatology (Oxford); 2022 Feb; 61(2):531-541. PubMed ID: 34382085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
    Paumier KL; Siderowf AD; Auinger P; Oakes D; Madhavan L; Espay AJ; Revilla FJ; Collier TJ;
    Mov Disord; 2012 Jun; 27(7):880-7. PubMed ID: 22555881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Type 2 Diabetes in Parkinson's Disease.
    Athauda D; Evans J; Wernick A; Virdi G; Choi ML; Lawton M; Vijiaratnam N; Girges C; Ben-Shlomo Y; Ismail K; Morris H; Grosset D; Foltynie T; Gandhi S
    Mov Disord; 2022 Aug; 37(8):1612-1623. PubMed ID: 35699244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.
    Gilat M; Coeytaux Jackson A; Marshall NS; Hammond D; Mullins AE; Hall JM; Fang BAM; Yee BJ; Wong KKH; Grunstein RR; Lewis SJG
    Mov Disord; 2020 Feb; 35(2):344-349. PubMed ID: 31674060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Videnovic A; Amara AW; Comella C; Schweitzer PK; Emsellem H; Liu K; Sterkel AL; Gottwald MD; Steinerman JR; Jochelson P; Zomorodi K; Hauser RA
    Mov Disord; 2021 Oct; 36(10):2408-2412. PubMed ID: 34191352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.